AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34427049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 34427049 — intervention group
Group type: EXPERIMENTAL
Intervention: ASP5354 (0.1 mg to 24 mg)
Number of subjects: 6
Study 33484515 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability exercises along with traditional therapy
Number of subjects: 24
Study 33484515 — intervention group
Group type: COMPARATOR
Intervention: Traditional low backache physical therapy
Number of subjects: 24
Study 34817871 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence from gaming for 7 days
Number of subjects: 50
Study 34817871 — intervention group
Group type: COMPARATOR
Intervention: Control group (no abstinence)
Number of subjects: 50
Study 33242498 — intervention group
Group type: EXPERIMENTAL
Intervention: Deficit-trained patients
Number of subjects: 48
Study 33242498 — intervention group
Group type: COMPARATOR
Intervention: Sighted-trained patients
Number of subjects: 48
Study 36250505 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 73
Study 36250505 — intervention group
Group type: COMPARATOR
Intervention: Stretching-and-toning (SAT, active control)
Number of subjects: 73
Study 33517744 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic articulation + liuzijue qigong (48 patients)
Number of subjects: 98
Study 33517744 — intervention group
Group type: COMPARATOR
Intervention: Basic articulation + traditional breathing training (50 patients)
Number of subjects: 98
Study 34138468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous polyspecific immunoglobulin G (IVIG) 25 g/d for 3 days
Number of subjects: 100
Study 34138468 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 36376474 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 200
Study 36376474 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study 32578261 — intervention group
Group type: EXPERIMENTAL
Intervention: Social story-based intervention
Number of subjects: 306
Study 32578261 — intervention group
Group type: COMPARATOR
Intervention: Standard leaflets (Control)
Number of subjects: 306
Study 34159507 — intervention group
Group type: EXPERIMENTAL
Intervention: FCU4Health
Number of subjects: 240
Study 34159507 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 240
Study 33225782 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate capsule
Number of subjects: 0
Study 33225782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35965813 — intervention group
Group type: EXPERIMENTAL
Intervention: Zengxiao Jiandu decoction combined with definitive concurrent chemoradiotherapy (DCCRT)
Number of subjects: 163
Study 35965813 — intervention group
Group type: COMPARATOR
Intervention: Control arm (DCCRT alone)
Number of subjects: 163
Study 36073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lists of concrete words
Number of subjects: 0
Study 36073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized lists of concrete words
Number of subjects: 0
Study 36073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed lists of abstract words
Number of subjects: 0
Study 36073985 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized lists of abstract words
Number of subjects: 0
Study 32561468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (40 IU) administered prior to each PE therapy session
Number of subjects: 0
Study 32561468 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered prior to each PE therapy session
Number of subjects: 0
Study 36421994 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole Phaeodactylum tricornutum (PT)
Number of subjects: 19
Study 36421994 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐1,3‐glucan‐rich PT supernatant (SupB)
Number of subjects: 19
Study 36421994 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Whole PT and SupB (A+SupB)
Number of subjects: 19
Study 36421994 — intervention group
Group type: COMPARATOR
Intervention: Comparator product (Comp)
Number of subjects: 19
Study 33210309 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemostasis Traffic Light
Number of subjects: 84
Study 33210309 — intervention group
Group type: COMPARATOR
Intervention: Text-based algorithm
Number of subjects: 84
Study 32220355 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcumin 500 mg/day for 12 weeks
Number of subjects: 60
Study 35144238 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week motivational interviewing and cognitive-behavioral intervention delivered in secret Facebook groups by electronic health coaches (e-coaches)
Number of subjects: 149
Study 35144238 — intervention group
Group type: COMPARATOR
Intervention: 8-week attention-placebo control condition
Number of subjects: 149
Study 33729546 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX (all three agents)
Number of subjects: 2246
Study 33729546 — intervention group
Group type: COMPARATOR
Intervention: 5‐FU/LV (only 5‐fluorouracil and leucovorin)
Number of subjects: 2246
Study 33957160 — intervention group
Group type: EXPERIMENTAL
Intervention: Classical olfactory training (OT) with 4 fixed odors
Number of subjects: 25
Study 33957160 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified olfactory training (OT) with 4 sets of 4 different odors sequentially
Number of subjects: 25
Study 33957160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 25
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation induction upon study entry
Number of subjects: 7899
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirming text notifications during quit attempt
Number of subjects: 7899
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous self-affirmation
Number of subjects: 7899
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline sadness
Number of subjects: 7899
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimism
Number of subjects: 7899
Study 33666561 — intervention group
Group type: EXPERIMENTAL
Intervention: Happiness and anger
Number of subjects: 7899
Study 33666561 — intervention group
Group type: COMPARATOR
Intervention: Conventional notifications
Number of subjects: 7899
Study 35102971 — intervention group
Group type: COMPARATOR
Intervention: Formocresol pulpotomy
Number of subjects: 68
Study 35102971 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser photobiomodulation pulpotomy
Number of subjects: 68
Study 34126156 — intervention group
Group type: EXPERIMENTAL
Intervention: REGN5713/14/15 (900 mg)
Number of subjects: 64
Study 34126156 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 33394214 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (LAN) 60 mg p.o. bid for one week before starting each cycle + R‐CHOP
Number of subjects: 60
Study 33394214 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine (FAM) 40 mg p.o. once daily one week before cycle and continues daily through the cycle + R‐CHOP for six cycles
Number of subjects: 60
Study 33394214 — intervention group
Group type: COMPARATOR
Intervention: Control group received R‐CHOP standard chemotherapy
Number of subjects: 60
Study 35690876 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming intervention (12-week program, three 30-min sessions per week using Xbox Kinect activity-based games)
Number of subjects: 0
Study 35690876 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (standard model of care delivered by the Justice Health and Forensic Mental Health Network)
Number of subjects: 0
Study 32646967 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported physical activity
Number of subjects: 377234
Study 32646967 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerometer-measured physical activity
Number of subjects: 377234
Study 32646967 — intervention group
Group type: EXPERIMENTAL
Intervention: Histologic types of lung cancer
Number of subjects: 377234
Study 35501170 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) present in patients with T1DM
Number of subjects: 978
Study 35501170 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated waist circumference in patients with MetS
Number of subjects: 978
Study 34050701 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS (30 min/day for 14 days)
Number of subjects: 37
Study 34050701 — intervention group
Group type: COMPARATOR
Intervention: Sham 1-Hz rTMS (30 min/day for 14 days)
Number of subjects: 37
Study 34050701 — intervention group
Group type: EXPERIMENTAL
Intervention: Real 1-Hz rTMS
Number of subjects: 37
Study 34050701 — intervention group
Group type: COMPARATOR
Intervention: Sham 1-Hz rTMS
Number of subjects: 37
Study 32267847 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line antiretroviral therapy
Number of subjects: 31
Study 35292944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (20 mg twice daily)
Number of subjects: 173
Study 35292944 — intervention group
Group type: COMPARATOR
Intervention: Low dose aspirin (80 mg) and calcium (1 g) daily
Number of subjects: 173
Study 33277284 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous caffeine (20 mg/kg)
Number of subjects: 40
Study 33277284 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral caffeine (20 mg/kg)
Number of subjects: 40
Study 33277284 — intervention group
Group type: COMPARATOR
Intervention: Intravenous caffeine
Number of subjects: 40
Study 33277284 — intervention group
Group type: COMPARATOR
Intervention: Enteral caffeine
Number of subjects: 40
Study 35534081 — intervention group
Group type: EXPERIMENTAL
Intervention: Wilderness programme (n=20)
Number of subjects: 40
Study 35534081 — intervention group
Group type: COMPARATOR
Intervention: Holiday programme (n=20)
Number of subjects: 40
Study 34230034 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of trial recruitment process into a clinical care pathway (CCP)
Number of subjects: 158
Study 32469385 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/d for 36 months
Number of subjects: 400
Study 32469385 — intervention group
Group type: COMPARATOR
Intervention: Imatinib 400 mg/d for 12 months
Number of subjects: 400
Study 32469385 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy population (36-month group)
Number of subjects: 400
Study 32469385 — intervention group
Group type: COMPARATOR
Intervention: Efficacy population (12-month group)
Number of subjects: 400
Study 35193873 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-hold (2-week methotrexate discontinuation after each vaccine dose)
Number of subjects: 138
Study 35193873 — intervention group
Group type: COMPARATOR
Intervention: MTX-maintain (methotrexate maintenance)
Number of subjects: 138
Study 35193873 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX-hold
Number of subjects: 138
Study 35193873 — intervention group
Group type: COMPARATOR
Intervention: MTX-maintain
Number of subjects: 138
Study 34789807 — intervention group
Group type: COMPARATOR
Intervention: Blephasteam (n=37)
Number of subjects: 70
Study 34789807 — intervention group
Group type: COMPARATOR
Intervention: TheraPearl (n=33)
Number of subjects: 70
Study 34789807 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Blephasteam and TheraPearl
Number of subjects: 70
Study 32540150 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 49
Study 32540150 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (SG)
Number of subjects: 49
Study 36226886 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational program on home birth
Number of subjects: 226
Study 36226886 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 226
Study 33129736 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density category A (lowest breast density)
Number of subjects: 3272
Study 33129736 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density category B
Number of subjects: 3272
Study 33129736 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density category C
Number of subjects: 3272
Study 33129736 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast density category D (highest breast density)
Number of subjects: 3272
Study 32191506 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% lidocaine, 10% prilocaine, and 4% tetracaine (experimental)
Number of subjects: 52
Study 32191506 — intervention group
Group type: COMPARATOR
Intervention: 20% benzocaine (control)
Number of subjects: 52
Study 32191506 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 35219462 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed crowns with biocompatible light-curing composite
Number of subjects: 50
Study 35219462 — intervention group
Group type: COMPARATOR
Intervention: Direct composite celluloid crowns
Number of subjects: 50
Study 35219462 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-printed crowns
Number of subjects: 50
Study 35219462 — intervention group
Group type: EXPERIMENTAL
Intervention: Both crown types
Number of subjects: 50
Study 33478652 — intervention group
Group type: COMPARATOR
Intervention: No compression (NONE)
Number of subjects: 30
Study 33478652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower leg compression (LEG)
Number of subjects: 30
Study 33478652 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal/thigh compression (ABDO)
Number of subjects: 30
Study 33478652 — intervention group
Group type: EXPERIMENTAL
Intervention: Full abdominal/leg compression (FULL)
Number of subjects: 30
Study 33478652 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression garments (various types)
Number of subjects: 30
Study 34700388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus SABR (240mg nivolumab every 2 weeks + SABR 18-20 Gy on day 8-14 of cycle 1)
Number of subjects: 50
Study 34700388 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab alone (240mg nivolumab every 2 weeks)
Number of subjects: 50
Study 35639672 — intervention group
Group type: EXPERIMENTAL
Intervention: LifeBuoy (therapeutic smartphone application based on dialectical behavior therapy)
Number of subjects: 455
Study 35639672 — intervention group
Group type: COMPARATOR
Intervention: LifeBuoy-C (attention-matched control application delivering general health information)
Number of subjects: 455
Study 32640037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric estimation and two-sample testing for population-averaged transition and state occupation probabilities
Number of subjects: 0
Study 32640037 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonparametric cluster bootstrap
Number of subjects: 0
Study 32640037 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed methods for multistate models
Number of subjects: 0
Study 32499466 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 doses of 1.2 g amoxicillin‐clavulanic acid
Number of subjects: 160
Study 32499466 — intervention group
Group type: COMPARATOR
Intervention: 7 days course of amoxicillin‐clavulanic acid and metronidazole
Number of subjects: 160
Study 35785543 — intervention group
Group type: EXPERIMENTAL
Intervention: Social needs case management for 12 months
Number of subjects: 57972
Study 34524031 — intervention group
Group type: EXPERIMENTAL
Intervention: All-arthroscopic (AA) rotator cuff repair
Number of subjects: 274
Study 34524031 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-open (MO) rotator cuff repair
Number of subjects: 274
Study 34524031 — intervention group
Group type: COMPARATOR
Intervention: Both AA and MO rotator cuff repair
Number of subjects: 274
Study 33305619 — intervention group
Group type: EXPERIMENTAL
Intervention: Early patient-directed rehabilitation (n=37); advised to remove their sling as soon as able and move as symptoms allow.
Number of subjects: 73
Study 33305619 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation (n=36); sling immobilisation for four weeks.
Number of subjects: 73
Study 33305619 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 12 weeks (both groups).
Number of subjects: 73
Study 33305619 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall randomisation and follow-up measures.
Number of subjects: 73
Study 33305619 — intervention group
Group type: EXPERIMENTAL
Intervention: Serious adverse events reported.
Number of subjects: 73
Study 33634628 — intervention group
Group type: EXPERIMENTAL
Intervention: Local infiltration with ropivacaine plus systemic analgesia
Number of subjects: 0
Study 33634628 — intervention group
Group type: COMPARATOR
Intervention: Saline infiltration into the surgical wound plus systemic analgesia
Number of subjects: 0
Study 35871321 — intervention group
Group type: EXPERIMENTAL
Intervention: Real cervical mobilization
Number of subjects: 28
Study 35871321 — intervention group
Group type: COMPARATOR
Intervention: Sham mobilization
Number of subjects: 28
Study 34635373 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-CRM liquid presentation
Number of subjects: 979
Study 34635373 — intervention group
Group type: COMPARATOR
Intervention: Currently licensed MenACWY-CRM vaccine presentation
Number of subjects: 979
Study 34635373 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 979
Study 35588504 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic mesh
Number of subjects: 108
Study 35588504 — intervention group
Group type: COMPARATOR
Intervention: Synthetic mesh
Number of subjects: 108
Study 35217408 — intervention group
Group type: EXPERIMENTAL
Intervention: IPTp-SP
Number of subjects: 105
Study 35217408 — intervention group
Group type: COMPARATOR
Intervention: IPTp-DP
Number of subjects: 105
Study 32275000 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal PEEP guided by FRC
Number of subjects: 78
Study 32275000 — intervention group
Group type: COMPARATOR
Intervention: Maximum oxygen monitoring (Control)
Number of subjects: 78
Study 32275000 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 78
Study 32275000 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 32275000 — intervention group
Group type: EXPERIMENTAL
Intervention: FRC and trans-pulmonary pressure
Number of subjects: 78
Study 35196147 — intervention group
Group type: EXPERIMENTAL
Intervention: Bandage contact lens soaked in 0.1% diclofenac
Number of subjects: 51
Study 35196147 — intervention group
Group type: COMPARATOR
Intervention: Normal soft bandage contact lens (control)
Number of subjects: 51
Study 34270328 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic advanced hybrid closed‐loop (AHCL)
Number of subjects: 113
Study 34270328 — intervention group
Group type: COMPARATOR
Intervention: First generation hybrid closed‐loop (HCL)
Number of subjects: 113
Study 34128383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment (crime)
Number of subjects: 495
Study 34128383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment (no streetlights)
Number of subjects: 495
Study 34128383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment (traffic)
Number of subjects: 495
Study 34128383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment (lack of nearby shops)
Number of subjects: 495
Study 34128383 — intervention group
Group type: EXPERIMENTAL
Intervention: Neighborhood environment (no one out doing PA)
Number of subjects: 495
Study 33811266 — intervention group
Group type: EXPERIMENTAL
Intervention: START intervention
Number of subjects: 176
Study 33811266 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 176
Study 35149125 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐based therapy for 96 weeks with 24-week off-treatment follow-up
Number of subjects: 80
Study 35149125 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐based therapy
Number of subjects: 80
Study 35149125 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of HBcrAg <4 log10U/ml and HBsAb >2 log10IU/L at EOT
Number of subjects: 80
Study 35149125 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower HBcrAg and higher HBsAb levels at EOT
Number of subjects: 80
Study 34960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D20SC 0‐1‐6
Number of subjects: 309
Study 34960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D20CHO 0‐1‐6
Number of subjects: 309
Study 34960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Group ND20SC 0‐1‐6
Number of subjects: 309
Study 34960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with one dose of hepatitis B vaccine containing 60 µg HBsAg
Number of subjects: 309
Study 34960153 — intervention group
Group type: EXPERIMENTAL
Intervention: Revaccination with one dose of hepatitis B vaccine containing 20 µg HBsAg
Number of subjects: 309
Study 34489210 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiotherapy (74 Gy/37 fractions/7.4 weeks)
Number of subjects: 3216
Study 34489210 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (60 Gy/20 fractions/4 weeks)
Number of subjects: 3216
Study 34489210 — intervention group
Group type: COMPARATOR
Intervention: Hypofractionated radiotherapy (57 Gy/19 fractions/3.8 weeks)
Number of subjects: 3216
Study 34489210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (60 Gy)
Number of subjects: 3216
Study 34489210 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (57 Gy)
Number of subjects: 3216
Study 34489210 — intervention group
Group type: EXPERIMENTAL
Intervention: All schedules
Number of subjects: 3216
Study 34791503 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led oral health intervention based on Health Belief Model and Social Cognitive Theory
Number of subjects: 1184
Study 34791503 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1184
Study 33678183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 ml ABHR volume
Number of subjects: 356
Study 33678183 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml ABHR volume
Number of subjects: 356
Study 33678183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 ml ABHR volume
Number of subjects: 356
Study 33678183 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 ml ABHR volume
Number of subjects: 356
Study 33678183 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.5 ml or more ABHR volume
Number of subjects: 356
Study 32527167 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 laser vaporization
Number of subjects: 16